Network meta-analysis

Systolic blood pressure change

Overweight or obesity without diabetes (adults)

weeks 40 to 104 (target week 68)Not stated by the trialsEach dose separatelyMean difference

Randomized trials

Treatments

4,816

Participants

Trial arms

In plain language

Across 17 trials with 4,816 participants, 9 of 14 treatments had a clearly better result than placebo on systolic blood pressure change, and for 5 the evidence could not tell them apart from placebo. The most favorable estimate was for tirzepatide 15 mg subcutaneous once weekly: mean difference -13.76 mmHg (95% credible interval -19.20 to -8.19).

Tirzepatide 15 mg subcutaneous once weekly: among the most effective (certainty pending).
Tirzepatide 10 mg subcutaneous once weekly: among the most effective (certainty pending).
Semaglutide 1.7 mg injection once weekly: better than placebo but not among the most effective (certainty pending).
Semaglutide 0.4 mg injection once daily: better than placebo but not among the most effective (certainty pending).
Semaglutide 2.4 mg subcutaneous once weekly: better than placebo but not among the most effective (certainty pending).
Semaglutide 50 mg oral once daily (higher dose oral program): better than placebo but not among the most effective (certainty pending).
Semaglutide 0.2 mg injection once daily: better than placebo but not among the most effective (certainty pending).
Semaglutide 0.3 mg injection once daily: better than placebo but not among the most effective (certainty pending).
Semaglutide 0.1 mg injection once daily: not convincingly different from placebo (certainty pending).
Liraglutide 3.0 mg subcutaneous once daily: better than placebo but not among the most effective (certainty pending).
Standard care or no added treatment: not convincingly different from placebo (certainty pending).
Semaglutide 0.05 mg injection once daily: not convincingly different from placebo (certainty pending).
Liraglutide 1.2 mg subcutaneous once daily: not convincingly different from placebo (certainty pending).
Liraglutide 1.8 mg subcutaneous once daily: not convincingly different from placebo (certainty pending).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Mean difference in mmHg. Lower values favor the treatment.

Versus Placebo. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian MD (95% CrI)	95% prediction interval	Frequentist MD (95% CI)	Verdict	Confidence
Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW	-13.76 (-19.20 to -8.19)	-20.62 to -6.73	-13.90 (-19.47 to -8.33)	Better	pending
Tirzepatide 10 mg subcutaneous once weekly TIRZ_SC_10MG_QW	-12.88 (-18.31 to -7.53)	-19.70 to -6.28	-13.10 (-18.74 to -7.46)	Better	pending
Semaglutide 1.7 mg injection once weekly SEMA_SC_1p7MG_QW	-7.08 (-11.88 to -2.32)	-13.61 to -0.92	-7.21 (-12.13 to -2.29)	Better	pending
Semaglutide 0.4 mg injection once daily SEMA_SC_0p4MG_QD	-6.36 (-10.79 to -2.12)	-12.55 to -0.60	-6.47 (-10.82 to -2.12)	Better	pending
Semaglutide 2.4 mg subcutaneous once weekly SEMA_SC_2p4MG_QW	-6.19 (-8.50 to -4.09)	-11.03 to -1.84	-6.37 (-8.62 to -4.13)	Better	pending
Semaglutide 50 mg oral once daily (higher dose oral program) SEMA_PO_50MG_QD	-6.00 (-10.56 to -1.18)	-12.17 to 0.38	-6.00 (-10.69 to -1.31)	Better	pending
Semaglutide 0.2 mg injection once daily SEMA_SC_0p2MG_QD	-4.59 (-9.28 to -0.19)	-10.96 to 1.53	-4.70 (-9.35 to -0.04)	Better	pending
Semaglutide 0.3 mg injection once daily SEMA_SC_0p3MG_QD	-4.55 (-8.96 to -0.37)	-10.88 to 1.27	-4.68 (-9.03 to -0.32)	Better	pending
Semaglutide 0.1 mg injection once daily SEMA_SC_0p1MG_QD	-4.07 (-8.77 to 0.30)	-10.25 to 2.00	-4.20 (-8.84 to 0.45)	Unclear	pending
Liraglutide 3.0 mg subcutaneous once daily LIRA_SC_3p0MG_QD	-3.70 (-6.09 to -1.75)	-8.91 to 0.58	-3.90 (-6.10 to -1.70)	Better	pending
Standard care or no added treatment STANDARD_CARE	-2.94 (-9.72 to 3.52)	-11.05 to 4.68	-3.20 (-10.14 to 3.74)	Unclear	pending
Semaglutide 0.05 mg injection once daily SEMA_SC_0p05MG_QD	-2.76 (-7.38 to 1.66)	-9.17 to 3.19	-2.90 (-7.56 to 1.77)	Unclear	pending
Liraglutide 1.2 mg subcutaneous once daily LIRA_SC_1p2MG_QD	-0.17 (-11.52 to 10.44)	-11.88 to 11.07	-0.50 (-11.78 to 10.78)	Unclear	pending
Liraglutide 1.8 mg subcutaneous once daily LIRA_SC_1p8MG_QD	0.44 (-5.60 to 6.50)	-6.94 to 7.75	0.50 (-5.82 to 6.82)	Unclear	pending

Confidence in the results

How much each comparison can be trusted, rated with CINeMA in six domains and summarized with GRADE.

Ratings follow the protocol's numeric rules from risk of bias and indirectness judgments made by language model reviewers (amendment A028); no human has verified them yet. Reporting bias (ROB-MEN): major concerns.

Confidence in each comparison with Placebo
Comparison	Within study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence
Liraglutide 1.2 mg subcutaneous once daily versus Placebo	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Placebo	pending	major	pending	major	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Placebo	pending	major	pending	some	none	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Placebo	pending	major	pending	some	none	some	pending
Semaglutide 0.1 mg injection once daily versus Placebo	pending	major	pending	some	none	some	pending
Semaglutide 0.2 mg injection once daily versus Placebo	pending	major	pending	some	none	some	pending
Semaglutide 0.3 mg injection once daily versus Placebo	pending	major	pending	some	none	some	pending
Semaglutide 0.4 mg injection once daily versus Placebo	pending	major	pending	none	some	some	pending
Semaglutide 0.05 mg injection once daily versus Placebo	pending	major	pending	some	some	some	pending
Semaglutide 1.7 mg injection once weekly versus Placebo	pending	major	pending	none	some	some	pending
Semaglutide 2.4 mg subcutaneous once weekly versus Placebo	pending	major	pending	none	some	some	pending
Standard care or no added treatment versus Placebo	pending	major	pending	major	none	some	pending
Tirzepatide 10 mg subcutaneous once weekly versus Placebo	pending	major	pending	none	none	some	pending
Tirzepatide 15 mg subcutaneous once weekly versus Placebo	pending	major	pending	none	none	some	pending

Every other comparison (91)

Confidence in the other comparisons
Comparison	Within study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence
Liraglutide 1.2 mg subcutaneous once daily versus Liraglutide 1.8 mg subcutaneous once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Liraglutide 3.0 mg subcutaneous once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Liraglutide 3.0 mg subcutaneous once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 50 mg oral once daily (higher dose oral program)	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 50 mg oral once daily (higher dose oral program)	pending	major	pending	some	some	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 50 mg oral once daily (higher dose oral program)	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 0.1 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 0.1 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.1 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Semaglutide 0.1 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.05 mg injection once daily versus Semaglutide 0.1 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 0.2 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 0.2 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.2 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Semaglutide 0.2 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.1 mg injection once daily versus Semaglutide 0.2 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.05 mg injection once daily versus Semaglutide 0.2 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 0.3 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 0.3 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.3 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Semaglutide 0.3 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.1 mg injection once daily versus Semaglutide 0.3 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.2 mg injection once daily versus Semaglutide 0.3 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.05 mg injection once daily versus Semaglutide 0.3 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 0.4 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 0.4 mg injection once daily	pending	major	pending	some	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.4 mg injection once daily	pending	major	pending	some	some	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Semaglutide 0.4 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.1 mg injection once daily versus Semaglutide 0.4 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.2 mg injection once daily versus Semaglutide 0.4 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.3 mg injection once daily versus Semaglutide 0.4 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 0.05 mg injection once daily versus Semaglutide 0.4 mg injection once daily	pending	major	pending	some	some	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 0.05 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 0.05 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.05 mg injection once daily	pending	major	pending	major	none	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Semaglutide 0.05 mg injection once daily	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	some	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	some	some	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.1 mg injection once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.2 mg injection once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.3 mg injection once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.4 mg injection once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.05 mg injection once daily versus Semaglutide 1.7 mg injection once weekly	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	some	some	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.1 mg injection once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.2 mg injection once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.3 mg injection once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.4 mg injection once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending
Semaglutide 0.05 mg injection once daily versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	some	some	some	pending
Semaglutide 1.7 mg injection once weekly versus Semaglutide 2.4 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 0.1 mg injection once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 0.2 mg injection once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 0.3 mg injection once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 0.4 mg injection once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 0.05 mg injection once daily versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 1.7 mg injection once weekly versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Semaglutide 2.4 mg subcutaneous once weekly versus Standard care or no added treatment	pending	major	pending	major	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	none	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	none	some	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.1 mg injection once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.2 mg injection once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.3 mg injection once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.4 mg injection once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.05 mg injection once daily versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	none	some	some	pending
Semaglutide 1.7 mg injection once weekly versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	some	some	pending
Semaglutide 2.4 mg subcutaneous once weekly versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Standard care or no added treatment versus Tirzepatide 10 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Liraglutide 1.2 mg subcutaneous once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Liraglutide 1.8 mg subcutaneous once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	none	none	some	pending
Liraglutide 3.0 mg subcutaneous once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	none	none	some	pending
Semaglutide 50 mg oral once daily (higher dose oral program) versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.1 mg injection once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	none	some	some	pending
Semaglutide 0.2 mg injection once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.3 mg injection once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	none	some	some	pending
Semaglutide 0.4 mg injection once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 0.05 mg injection once daily versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	none	none	some	pending
Semaglutide 1.7 mg injection once weekly versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Semaglutide 2.4 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	some	none	some	pending
Standard care or no added treatment versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	none	some	some	pending
Tirzepatide 10 mg subcutaneous once weekly versus Tirzepatide 15 mg subcutaneous once weekly	pending	major	pending	major	none	some	pending

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

Rank probabilities

Probability of each rank for each treatment
Treatment	Rank 1	Rank 2	Rank 3	Rank 4	Rank 5	Rank 6	Rank 7	Rank 8	Rank 9	Rank 10	Rank 11	Rank 12	Rank 13	Rank 14	Rank 15	Mean rank
TIRZ_SC_15MG_QW	60%	34%	3%	1%												1.5
TIRZ_SC_10MG_QW	36%	55%	6%	2%	1%											1.8
SEMA_SC_1p7MG_QW	2%	4%	33%	17%	11%	9%	7%	5%	4%	3%	2%	2%	1%			5.1
SEMA_SC_0p4MG_QD	1%	2%	17%	20%	17%	15%	10%	8%	4%	3%	2%	1%	1%			5.5
SEMA_SC_2p4MG_QW			8%	20%	24%	18%	13%	8%	5%	2%	1%					5.7
SEMA_PO_50MG_QD	1%	1%	15%	16%	14%	13%	10%	8%	7%	5%	4%	3%	2%	1%		6.3
SEMA_SC_0p2MG_QD		1%	4%	6%	8%	10%	12%	14%	12%	11%	9%	7%	4%	1%		8.1
SEMA_SC_0p3MG_QD		1%	2%	5%	8%	10%	14%	15%	14%	12%	9%	6%	3%	1%		8.2
SEMA_SC_0p1MG_QD			2%	4%	6%	9%	10%	12%	13%	14%	13%	9%	6%	2%	1%	8.9
LIRA_SC_3p0MG_QD					1%	4%	8%	13%	18%	22%	20%	10%	3%			9.6
STANDARD_CARE		1%	4%	5%	5%	5%	6%	6%	7%	8%	10%	16%	13%	11%	3%	10.0
SEMA_SC_0p05MG_QD			1%	1%	2%	3%	5%	6%	10%	13%	18%	19%	14%	7%	3%	10.7
LIRA_SC_1p2MG_QD	1%	1%	5%	3%	3%	2%	3%	3%	3%	4%	4%	7%	10%	13%	37%	11.8
LIRA_SC_1p8MG_QD					1%	1%	1%	2%	2%	3%	5%	9%	14%	24%	36%	13.2
PLACEBO										1%	2%	11%	29%	39%	19%	13.6

League table

Every treatment against every other: mean difference of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	TIRZ_SC_15MG_QW	TIRZ_SC_10MG_QW	SEMA_SC_1p7MG_QW	SEMA_SC_0p4MG_QD	SEMA_SC_2p4MG_QW	SEMA_PO_50MG_QD	SEMA_SC_0p2MG_QD	SEMA_SC_0p3MG_QD	SEMA_SC_0p1MG_QD	LIRA_SC_3p0MG_QD	STANDARD_CARE	SEMA_SC_0p05MG_QD	LIRA_SC_1p2MG_QD	LIRA_SC_1p8MG_QD
PLACEBO	PLACEBO	13.76 8.19 to 19.20	12.88 7.53 to 18.31	7.08 2.32 to 11.88	6.36 2.12 to 10.79	6.19 4.09 to 8.50	6.00 1.18 to 10.56	4.59 0.19 to 9.28	4.55 0.37 to 8.96	4.07 -0.30 to 8.77	3.70 1.75 to 6.09	2.94 -3.52 to 9.72	2.76 -1.66 to 7.38	0.17 -10.44 to 11.52	-0.44 -6.50 to 5.60
TIRZ_SC_15MG_QW	-13.76 -19.20 to -8.19	TIRZ_SC_15MG_QW	-0.80 -6.27 to 4.59	-6.69 -13.87 to 0.61	-7.38 -14.31 to -0.13	-7.55 -13.41 to -1.40	-7.77 -14.97 to -0.75	-9.18 -16.27 to -1.75	-9.19 -16.05 to -2.22	-9.65 -16.55 to -2.51	-10.03 -15.63 to -4.03	-10.73 -19.18 to -2.23	-10.97 -17.93 to -3.69	-13.54 -25.46 to -1.05	-14.16 -22.23 to -5.96
TIRZ_SC_10MG_QW	-12.88 -18.31 to -7.53	0.80 -4.59 to 6.27	TIRZ_SC_10MG_QW	-5.84 -13.01 to 1.47	-6.58 -13.60 to 0.78	-6.71 -12.55 to -0.52	-6.97 -14.20 to 0.06	-8.34 -15.34 to -1.16	-8.37 -15.35 to -1.25	-8.84 -15.81 to -1.62	-9.20 -14.87 to -3.19	-9.88 -18.73 to -1.17	-10.13 -17.29 to -2.88	-12.69 -24.96 to -0.15	-13.34 -21.66 to -5.12
SEMA_SC_1p7MG_QW	-7.08 -11.88 to -2.32	6.69 -0.61 to 13.87	5.84 -1.47 to 13.01	SEMA_SC_1p7MG_QW	-0.67 -7.10 to 5.67	-0.93 -5.45 to 3.95	-1.08 -7.96 to 5.32	-2.51 -9.02 to 4.14	-2.50 -8.92 to 3.83	-2.98 -9.40 to 3.61	-3.37 -8.34 to 1.97	-4.20 -12.14 to 4.14	-4.32 -10.96 to 2.36	-6.97 -18.42 to 5.44	-7.53 -15.22 to -0.03
SEMA_SC_0p4MG_QD	-6.36 -10.79 to -2.12	7.38 0.13 to 14.31	6.58 -0.78 to 13.60	0.67 -5.67 to 7.10	SEMA_SC_0p4MG_QD	-0.19 -4.88 to 4.71	-0.37 -6.98 to 5.83	-1.77 -6.57 to 3.19	-1.82 -6.65 to 2.75	-2.28 -7.20 to 2.66	-2.69 -6.87 to 1.81	-3.44 -11.06 to 4.15	-3.61 -8.42 to 1.34	-6.17 -17.52 to 5.61	-6.82 -14.35 to 0.60
SEMA_SC_2p4MG_QW	-6.19 -8.50 to -4.09	7.55 1.40 to 13.41	6.71 0.52 to 12.55	0.93 -3.95 to 5.45	0.19 -4.71 to 4.88	SEMA_SC_2p4MG_QW	-0.18 -5.76 to 4.80	-1.56 -6.59 to 3.52	-1.62 -6.57 to 3.14	-2.11 -7.11 to 2.88	-2.48 -5.32 to 0.54	-3.24 -10.08 to 3.73	-3.42 -8.44 to 1.59	-6.05 -16.76 to 5.43	-6.65 -13.05 to -0.36
SEMA_PO_50MG_QD	-6.00 -10.56 to -1.18	7.77 0.75 to 14.97	6.97 -0.06 to 14.20	1.08 -5.32 to 7.96	0.37 -5.83 to 6.98	0.18 -4.80 to 5.76	SEMA_PO_50MG_QD	-1.39 -7.71 to 5.38	-1.40 -7.73 to 5.08	-1.94 -8.37 to 5.05	-2.30 -7.22 to 3.35	-2.99 -10.83 to 5.13	-3.21 -9.59 to 3.57	-5.72 -17.13 to 6.12	-6.40 -13.97 to 1.29
SEMA_SC_0p2MG_QD	-4.59 -9.28 to -0.19	9.18 1.75 to 16.27	8.34 1.16 to 15.34	2.51 -4.14 to 9.02	1.77 -3.19 to 6.57	1.56 -3.52 to 6.59	1.39 -5.38 to 7.71	SEMA_SC_0p2MG_QD	-0.03 -5.18 to 4.90	-0.50 -5.66 to 4.44	-0.87 -5.40 to 3.81	-1.62 -9.42 to 6.13	-1.82 -6.94 to 3.30	-4.45 -15.78 to 7.50	-5.05 -12.79 to 2.33
SEMA_SC_0p3MG_QD	-4.55 -8.96 to -0.37	9.19 2.22 to 16.05	8.37 1.25 to 15.35	2.50 -3.83 to 8.92	1.82 -2.75 to 6.65	1.62 -3.14 to 6.57	1.40 -5.08 to 7.73	0.03 -4.90 to 5.18	SEMA_SC_0p3MG_QD	-0.45 -5.46 to 4.62	-0.86 -5.05 to 3.58	-1.57 -9.37 to 6.00	-1.79 -6.58 to 3.19	-4.40 -15.63 to 7.37	-5.00 -12.58 to 2.32
SEMA_SC_0p1MG_QD	-4.07 -8.77 to 0.30	9.65 2.51 to 16.55	8.84 1.62 to 15.81	2.98 -3.61 to 9.40	2.28 -2.66 to 7.20	2.11 -2.88 to 7.11	1.94 -5.05 to 8.37	0.50 -4.44 to 5.66	0.45 -4.62 to 5.46	SEMA_SC_0p1MG_QD	-0.40 -4.85 to 4.21	-1.12 -8.77 to 6.54	-1.30 -6.46 to 3.80	-3.98 -15.03 to 7.80	-4.53 -12.25 to 2.92
LIRA_SC_3p0MG_QD	-3.70 -6.09 to -1.75	10.03 4.03 to 15.63	9.20 3.19 to 14.87	3.37 -1.97 to 8.34	2.69 -1.81 to 6.87	2.48 -0.54 to 5.32	2.30 -3.35 to 7.22	0.87 -3.81 to 5.40	0.86 -3.58 to 5.05	0.40 -4.21 to 4.85	LIRA_SC_3p0MG_QD	-0.74 -7.21 to 5.55	-0.93 -5.67 to 3.51	-3.57 -14.05 to 7.34	-4.16 -10.79 to 2.19
STANDARD_CARE	-2.94 -9.72 to 3.52	10.73 2.23 to 19.18	9.88 1.17 to 18.73	4.20 -4.14 to 12.14	3.44 -4.15 to 11.06	3.24 -3.73 to 10.08	2.99 -5.13 to 10.83	1.62 -6.13 to 9.42	1.57 -6.00 to 9.37	1.12 -6.54 to 8.77	0.74 -5.55 to 7.21	STANDARD_CARE	-0.17 -8.07 to 7.41	-2.69 -11.66 to 6.10	-3.47 -12.80 to 5.48
SEMA_SC_0p05MG_QD	-2.76 -7.38 to 1.66	10.97 3.69 to 17.93	10.13 2.88 to 17.29	4.32 -2.36 to 10.96	3.61 -1.34 to 8.42	3.42 -1.59 to 8.44	3.21 -3.57 to 9.59	1.82 -3.30 to 6.94	1.79 -3.19 to 6.58	1.30 -3.80 to 6.46	0.93 -3.51 to 5.67	0.17 -7.41 to 8.07	SEMA_SC_0p05MG_QD	-2.58 -13.83 to 9.20	-3.19 -10.66 to 4.26
LIRA_SC_1p2MG_QD	-0.17 -11.52 to 10.44	13.54 1.05 to 25.46	12.69 0.15 to 24.96	6.97 -5.44 to 18.42	6.17 -5.61 to 17.52	6.05 -5.43 to 16.76	5.72 -6.12 to 17.13	4.45 -7.50 to 15.78	4.40 -7.37 to 15.63	3.98 -7.80 to 15.03	3.57 -7.34 to 14.05	2.69 -6.10 to 11.66	2.58 -9.20 to 13.83	LIRA_SC_1p2MG_QD	-0.56 -13.43 to 11.41
LIRA_SC_1p8MG_QD	0.44 -5.60 to 6.50	14.16 5.96 to 22.23	13.34 5.12 to 21.66	7.53 0.03 to 15.22	6.82 -0.60 to 14.35	6.65 0.36 to 13.05	6.40 -1.29 to 13.97	5.05 -2.33 to 12.79	5.00 -2.32 to 12.58	4.53 -2.92 to 12.25	4.16 -2.19 to 10.79	3.47 -5.48 to 12.80	3.19 -4.26 to 10.66	0.56 -11.41 to 13.43	LIRA_SC_1p8MG_QD

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 1.640 (95% CrI 0.129 to 3.900)
Residual deviance: 42.5 for 42 data points
DIC: 78.4 (pD 35.9)
Largest R-hat: 1.003
Smallest ESS: bulk 1,101, tail 2,078
Divergent transitions: 0
Convergence: All criteria met
Priors: PR01 N(0, 60^2); PR03 N(0, 30^2); PR07 half normal(0, 6^2) on tau

Frequentist check (netmeta)

Method: inverse variance, REML, MD
Tau: 2.107
I squared: 39%
Q (total): 18.09 on 11 df, P = 0.080
Q (between designs): 11.37, P = 0.023

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

Frequentist node splitting (Back-calculation). A small P value means direct and indirect evidence disagree.
Comparison	Trials	Direct	Indirect	Network	P
Liraglutide 3.0 mg subcutaneous once daily versus Placebo LIRA_SC_3p0MG_QD:PLACEBO	7	-4.23 -6.49 to -1.98	3.09 -7.26 to 13.43	-3.90 -6.10 to -1.70	0.175
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.05 mg injection once daily LIRA_SC_3p0MG_QD:SEMA_SC_0p05MG_QD	1	-0.99 -6.28 to 4.30	-1.07 -11.25 to 9.12	-1.01 -5.70 to 3.68	0.989
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.1 mg injection once daily LIRA_SC_3p0MG_QD:SEMA_SC_0p1MG_QD	1	0.31 -4.96 to 5.58	0.23 -9.88 to 10.34	0.29 -4.38 to 4.96	0.989
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.2 mg injection once daily LIRA_SC_3p0MG_QD:SEMA_SC_0p2MG_QD	1	0.81 -4.47 to 6.09	0.73 -9.41 to 10.88	0.79 -3.89 to 5.47	0.989
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.3 mg injection once daily LIRA_SC_3p0MG_QD:SEMA_SC_0p3MG_QD	1	0.79 -4.22 to 5.80	0.72 -8.29 to 9.73	0.77 -3.61 to 5.15	0.989
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 0.4 mg injection once daily LIRA_SC_3p0MG_QD:SEMA_SC_0p4MG_QD	1	2.58 -2.42 to 7.59	2.51 -6.48 to 11.51	2.57 -1.81 to 6.94	0.989
Liraglutide 3.0 mg subcutaneous once daily versus Semaglutide 2.4 mg subcutaneous once weekly LIRA_SC_3p0MG_QD:SEMA_SC_2p4MG_QW	1	3.00 -2.60 to 8.60	2.26 -1.24 to 5.76	2.47 -0.50 to 5.44	0.827
Semaglutide 0.05 mg injection once daily versus Placebo SEMA_SC_0p05MG_QD:PLACEBO	1	-2.88 -8.05 to 2.29	-2.96 -13.81 to 7.89	-2.90 -7.56 to 1.77	0.989
Semaglutide 0.1 mg injection once daily versus Placebo SEMA_SC_0p1MG_QD:PLACEBO	1	-4.18 -9.33 to 0.97	-4.26 -15.03 to 6.50	-4.20 -8.84 to 0.45	0.989
Semaglutide 0.2 mg injection once daily versus Placebo SEMA_SC_0p2MG_QD:PLACEBO	1	-4.68 -9.84 to 0.48	-4.76 -15.57 to 6.04	-4.70 -9.35 to -0.04	0.989
Semaglutide 0.3 mg injection once daily versus Placebo SEMA_SC_0p3MG_QD:PLACEBO	1	-4.66 -9.55 to 0.23	-4.73 -14.30 to 4.84	-4.68 -9.03 to -0.32	0.989
Semaglutide 0.4 mg injection once daily versus Placebo SEMA_SC_0p4MG_QD:PLACEBO	1	-6.46 -11.34 to -1.57	-6.53 -16.08 to 3.02	-6.47 -10.82 to -2.12	0.989
Semaglutide 1.7 mg injection once weekly versus Placebo SEMA_SC_1p7MG_QW:PLACEBO	1	-7.00 -12.68 to -1.32	-7.84 -17.64 to 1.96	-7.21 -12.13 to -2.29	0.884
Semaglutide 2.4 mg subcutaneous once weekly versus Placebo SEMA_SC_2p4MG_QW:PLACEBO	6	-6.61 -8.91 to -4.31	-1.79 -11.88 to 8.29	-6.37 -8.62 to -4.13	0.361
Semaglutide 1.7 mg injection once weekly versus Semaglutide 2.4 mg subcutaneous once weekly SEMA_SC_1p7MG_QW:SEMA_SC_2p4MG_QW	1	-1.00 -6.31 to 4.31	-0.03 -11.93 to 11.87	-0.84 -5.69 to 4.01	0.884

Heterogeneity within designs (decomp.design)
Design	Q	df	P
PLACEBO:LIRA_SC_3p0MG_QD	3.81	4	0.432
PLACEBO:SEMA_SC_2p4MG_QW	2.90	3	0.407

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Comparisons ordered as LIRA_SC_1p2MG_QD, LIRA_SC_1p8MG_QD, LIRA_SC_3p0MG_QD, SEMA_PO_50MG_QD, SEMA_SC_0p05MG_QD, SEMA_SC_0p1MG_QD, SEMA_SC_0p2MG_QD, SEMA_SC_0p3MG_QD, SEMA_SC_0p4MG_QD, SEMA_SC_1p7MG_QW, SEMA_SC_2p4MG_QW, STANDARD_CARE, TIRZ_SC_10MG_QW, TIRZ_SC_15MG_QW, PLACEBO; the shaded triangle is where 95% of points would fall without small study effects. Egger type test P = 0.016.

Contribution of direct evidence

Percent contribution of each direct comparison (columns) to each network estimate (rows), from netcontrib.

Contribution of direct comparisons to network estimates
Network estimate	LIRA_SC_1p2MG_QD:STANDARD_CARE	LIRA_SC_1p8MG_QD:PLACEBO	LIRA_SC_3p0MG_QD:PLACEBO	LIRA_SC_3p0MG_QD:PLACEBO:SEMA_SC_0p05MG_QD:SEMA_SC_0p1MG_QD:SEMA_SC_0p2MG_QD:SEMA_SC_0p3MG_QD:SEMA_SC_0p4MG_QD	LIRA_SC_3p0MG_QD:PLACEBO:SEMA_SC_2p4MG_QW	LIRA_SC_3p0MG_QD:STANDARD_CARE	PLACEBO:SEMA_PO_50MG_QD	PLACEBO:SEMA_SC_1p7MG_QW:SEMA_SC_2p4MG_QW	PLACEBO:SEMA_SC_2p4MG_QW	PLACEBO:TIRZ_SC_10MG_QW:TIRZ_SC_15MG_QW
LIRA_SC_1p2MG_QD:PLACEBO	31		20	9	6	31		1	2
LIRA_SC_1p8MG_QD:PLACEBO		100
LIRA_SC_3p0MG_QD:PLACEBO			59	21	15			1	3
PLACEBO:SEMA_PO_50MG_QD							100
PLACEBO:SEMA_SC_0p05MG_QD			12	84	3				1
PLACEBO:SEMA_SC_0p1MG_QD			12	84	3				1
PLACEBO:SEMA_SC_0p2MG_QD			12	84	3				1
PLACEBO:SEMA_SC_0p3MG_QD			12	84	3				1
PLACEBO:SEMA_SC_0p4MG_QD			12	84	3				1
PLACEBO:SEMA_SC_1p7MG_QW			1	1	5			76	17
PLACEBO:SEMA_SC_2p4MG_QW			3	1	17			19	60
PLACEBO:STANDARD_CARE			30	13	9	46		1	2
PLACEBO:TIRZ_SC_10MG_QW										100
PLACEBO:TIRZ_SC_15MG_QW										100

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 12 of 17
S-LITE S000371	32.62
BARI-STEP S000434	41.5
SCALE™ IBT S000712	39
STEP 10 S000832	39.9
NCT03038620 S000866	37.65
STEP 3 S000988	38
SURMOUNT-J S001216	33.5
NCT00781937 S001278	35.6
STEP7 S001288	not reported
NCT01795248 S001419	31.28
OASIS 1 S001472	not reported
STEP 8 S001600	not reported
STRIVE S001687	45.96
STEP 6 S002102	not reported
NCT02453711 S002317	body weight 111.5 kg
S003017 S003017	38.05
S003075 S003075	30.27

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Baseline BMI or body weight: not reported by 5 of 17 trials
FlagBaseline, Baseline BMI or body weight: design means range from 30.3 (LIRA_SC_1p2MG_QD vs STANDARD_CARE) to 46.0 (LIRA_SC_3p0MG_QD vs STANDARD_CARE) kg/m2; threshold 3
NoteOutcome assessment, time point: selected time points span 40 to 72 weeks
NoteOutcome assessment, analysis set: mixed: completers 3, full_analysis 9, modified_itt 2, other 2, per_protocol 1
NoteOutcome assessment, definition: mixed: change in systolic blood pressure 2, change in systolic blood pressure from baseline (registry description) 1, not stated 13, observed mean change in systolic blood pressure 1
NoteRisk of bias, blinding: mixed: double_blind 15, open_label 1, single_blind 1
NoteRisk of bias, funding: mixed: industry 13, mixed 4
NoteData handling, input conversions: arms_combined 4

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
S-LITE	52	per_protocol	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2016	age 18 to 65; BMI 32 to 43; no diabetes; at least 5 percent loss on 8 week low calorie diet
BARI-STEP	68	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2022	age 18 to 65; at least 1 year after primary bypass or sleeve; less than 20 percent weight loss from surgery
SCALE™ IBT	56	full_analysis	observed mean change in systolic blood pressure	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 30 or more; no diabetes; HbA1c below 6.5 percent; stable weight
STEP 10	52	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Adults with obesity and prediabetes; diabetes excluded
NCT03038620	40	completers	change in systolic blood pressure from baseline (registry description)	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 35 or more; BMI 30 or more, or 27 or more with metabolic syndrome; no diabetes
STEP 3	68	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	BMI 30 or more, or 27 with comorbidity; no type 2 diabetes
SURMOUNT-J	72	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 20 or more; BMI 27 to below 35 with 2 or more ORHDs or BMI 35 or more with 1 or more; no diabetes
NCT00781937	56	full_analysis	change in systolic blood pressure	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	BMI 30 or more or 27 with comorbidity; no diabetes; at least 5 percent loss on run in
STEP7	44	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 or older; BMI 30 or more, or 27 or more with a weight related comorbidity including T2D
NCT01795248	52.18	completers	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2012	women with prior gestational diabetes; no diabetes; overweight or obese
OASIS 1	68	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	overweight or obesity
STEP 8	68	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 or older; BMI 30 or higher, or 27 with a weight related comorbidity; no type 2 diabetes
STRIVE	52	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2017	age 18 to 75; BMI 35 or more plus prediabetes, T2D, hypertension or sleep apnea; no insulin or GLP-1 RA
STEP 6	68	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019
NCT02453711	52	full_analysis	change in systolic blood pressure	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	BMI 30 or more without diabetes
S003017	52.14	other	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 20 to 65; BMI above 35; 12 to 36 months after bariatric surgery with suboptimal stable weight loss or regain
S003075	52	other	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	mixed	2011	age 18 to 65; BMI 30 to 40; healthy; fasting glucose below 7 mmol/L

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Value	SE	Events / N	Flags	Source
S-LITE	A1+A2	PLACEBO	52	arm, change	4.020	1.867	65	arms_combined	R0007438:Table 2
S-LITE	A3+A4	LIRA_SC_3p0MG_QD	52	arm, change	0.148	1.884	65	arms_combined	R0007438:Table 2
BARI-STEP	A1	PLACEBO	68	arm, change	2.000	3.100	28		R0014003:Table 2
BARI-STEP	A2	SEMA_SC_2p4MG_QW	68	arm, change	-3.900	3.300	34		R0014003:Table 2
SCALE™ IBT	A1	LIRA_SC_3p0MG_QD	56	arm, change	-2.000	1.175	142		registry:outcomes
SCALE™ IBT	A2	PLACEBO	56	arm, change	-1.000	1.099	140		registry:outcomes
STEP 10	A1	SEMA_SC_2p4MG_QW	52	arm, change	-9.000	1.145	129		registry:outcomes
STEP 10	A2	PLACEBO	52	arm, change	-1.000	1.600	66		registry:outcomes
NCT03038620	A1	LIRA_SC_3p0MG_QD	40	arm, change	-5.840	2.104	73		registry:outcomes
NCT03038620	A2	PLACEBO	40	arm, change	-0.020	2.159	55		registry:outcomes
STEP 3	A1	SEMA_SC_2p4MG_QW	68	arm, change	-6.000	0.726	372		registry:outcomes
STEP 3	A2	PLACEBO	68	arm, change	-2.000	1.094	188		registry:outcomes
SURMOUNT-J	A1	PLACEBO	72	arm, change	1.900	1.350	66		registry:outcomes
SURMOUNT-J	A2	TIRZ_SC_10MG_QW	72	arm, change	-11.200	1.420	59		registry:outcomes
SURMOUNT-J	A3	TIRZ_SC_15MG_QW	72	arm, change	-12.000	1.350	65		registry:outcomes
NCT00781937	A1	LIRA_SC_3p0MG_QD	56	arm, change	1.310	0.900	207		registry:outcomes
NCT00781937	A2	PLACEBO	56	arm, change	4.030	0.870	206		registry:outcomes
STEP7	A1	SEMA_SC_2p4MG_QW	44	arm, change	-7.000	0.778	238		registry:outcomes
STEP7	A2	PLACEBO	44	arm, change	-2.000	1.114	116		registry:outcomes
NCT01795248	A1	PLACEBO	52.18	arm, change	-6.900	1.633	45		R0007651:Table 1
NCT01795248	A2	LIRA_SC_1p8MG_QD	52.18	arm, change	-6.400	1.811	37		R0007651:Table 1
OASIS 1	A1	SEMA_PO_50MG_QD	68	arm, change	-7.000	0.786	317		registry:outcomes
OASIS 1	A2	PLACEBO	68	arm, change	-1.000	0.815	295		registry:outcomes
STEP 8	A1	SEMA_SC_2p4MG_QW	68	arm, change	-7.000	1.311	114		registry:outcomes
STEP 8	A2	LIRA_SC_3p0MG_QD	68	arm, change	-4.000	1.417	112		registry:outcomes
STEP 8	A3	PLACEBO	68	arm, change	5.000	1.595	77		registry:outcomes
STRIVE	A1	STANDARD_CARE	52	arm, change	-3.200	2.197	62		R0020855:Table 3
STRIVE	A2	LIRA_SC_3p0MG_QD	52	arm, change	-3.900	1.416	139		R0020855:Table 3
STEP 6	A1	SEMA_SC_1p7MG_QW	68	arm, change	-12.000	1.313	98		registry:outcomes
STEP 6	A2	SEMA_SC_2p4MG_QW	68	arm, change	-11.000	1.080	193		registry:outcomes
STEP 6	A3	PLACEBO	68	arm, change	-5.000	1.500	100		registry:outcomes
NCT02453711	A1	SEMA_SC_0p05MG_QD	52	arm, change	-4.460	1.200	91		registry:outcomes
NCT02453711	A2	SEMA_SC_0p1MG_QD	52	arm, change	-5.760	1.180	96		registry:outcomes
NCT02453711	A3	SEMA_SC_0p2MG_QD	52	arm, change	-6.260	1.190	94		registry:outcomes
NCT02453711	A4+A6	SEMA_SC_0p3MG_QD	52	arm, change	-6.240	0.839	190	arms_combined	registry:outcomes
NCT02453711	A5+A7	SEMA_SC_0p4MG_QD	52	arm, change	-8.035	0.833	200	arms_combined	registry:outcomes
NCT02453711	A8	LIRA_SC_3p0MG_QD	52	arm, change	-5.450	1.180	96		registry:outcomes
NCT02453711	A9	PLACEBO	52	arm, change	-1.580	1.040	123		registry:outcomes
S003017	A1	LIRA_SC_3p0MG_QD	52.14	arm, final	124.000	3.098	15		R0016758:Table 1
S003017	A2	PLACEBO	52.14	arm, final	133.000	4.243	8		R0016758:Table 1
S003075	A1	LIRA_SC_1p2MG_QD	52	arm, change	9.900	3.087			R0018258:Results
S003075	A2	STANDARD_CARE	52	arm, change	7.200	2.577			R0018258:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab